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whether there is a dedicated, unique 
transmembrane receptor for AOPPs 
remains an open question. Earlier studies 
have shown that AOPPs are capable of 
using the receptor for advanced glycation 
end products (RAGE) for their signaling 
in vascular endothelial cells. 7 Likewise, 
AOPPs could use CD36, a class B trans-
membrane multiligand scavenger receptor 
that binds to oxidized proteins and is 
induced in renal tubular epithelial cells in 
CKD, for transmitting their signals. 12 
In this context, it is conceivable that 
AOPPs may induce podocyte apoptosis 
by using RAGE or CD36 receptors. As 
both RAGE and CD36-knockout mice 
are currently available, one might antici-
pate a defi nite answer to this postulation 
in the near future. 
 Th e fi ndings presented by Zhou and 
colleagues could have broad implications 
in our understanding of the pathogenesis 
of podocyte depletion and proteinuria in 
CKD. As end-stage kidney disease is now 
recognized to be associated with states 
of increased oxidative stress, AOPP-
mediated podocyte apoptosis would 
undoubtedly play a critical role in pro-
moting proteinuria and accelerating 
glomerulosclerosis, although it remains 
uncertain whether this pathway is active 
and operated in the early stage of kidney 
disease. In addition, many pathogenic 
factors, such as hyperglycemia, angi-
otensin II, and transforming growth fac-
tor-  1, are able to trigger intracellular 
superoxide generation. Th erefore, the 
signal cascade elucidated in this study 
might potentially be a convergent path-
way leading to podocyte depletion in 
CKD patients. 
 Given that inhibition of NADPH oxidase 
with apocynin eff ectively protects podo-
cytes from AOPP-mediated apoptosis  in 
vivo and  in vitro , strategies aimed at reduc-
ing oxidative stress might prevent podocyte 
loss, thereby blocking the progression of 
CKD in the clinical setting . 
 DISCLOSURE 
 The author declared no competing interests . 
 REFERENCES 
 1 .  Okamura  DM ,  Himmelfarb  J .  Tipping the redox 
balance of oxidative stress in fibrogenic pathways 
in chronic kidney disease .  Pediatr Nephrol  advance 
online publication, 7 May 2009, doi:10.1007/
s00467-00009-01199-00465 . 
 2 .  Forbes  JM ,  Coughlan  MT ,  Cooper  ME .  Oxidative 
stress as a major culprit in kidney disease in 
diabetes .  Diabetes  2008 ;  57 :  1446 – 1454 . 
 3 .  Witko-Sarsat  V ,  Friedlander  M ,  Capeillere-Blandin 
 C  et al.  Advanced oxidation protein products as a 
novel marker of oxidative stress in uremia .  Kidney 
Int  1996 ;  49 :  1304 – 1313 . 
 4 .  Descamps-Latscha  B ,  Witko-Sarsat  V ,  Nguyen-
Khoa  T  et al.  Early prediction of IgA nephropathy 
progression: proteinuria and AOPP are strong 
prognostic markers .  Kidney Int  2004 ;  66 :  1606 – 1612 . 
 5 .  Li  HY ,  Hou  FF ,  Zhang  X  et al.  Advanced oxidation 
protein products accelerate renal fibrosis in a remnant 
kidney model .  J Am Soc Nephrol  2007 ;  18 :  528 – 538 . 
 6 .  Descamps-Latscha  B ,  Witko-Sarsat  V ,  Nguyen-
Khoa  T  et al.  Advanced oxidation protein products 
as risk factors for atherosclerotic cardiovascular 
events in nondiabetic predialysis patients .  Am J 
Kidney Dis  2005 ;  45 :  39 – 47 . 
 7 .  Guo  ZJ ,  Niu  HX ,  Hou  FF  et al.  Advanced oxidation 
protein products activate vascular endothelial 
cells via a RAGE-mediated signaling pathway . 
 Antioxid Redox Signal  2008 ;  10 :  1699 – 1712 . 
 8 .  Peng  KF ,  Wu  XF ,  Zhao  HW  et al.  Advanced 
oxidation protein products induce monocyte 
chemoattractant protein-1 expression via p38 
mitogen-activated protein kinase activation in 
rat vascular smooth muscle cells .  Chin Med J  2006 ; 
 119 :  1088 – 1093 . 
 9 .  Zhou  LL ,  Hou  FF ,  Wang  GB  et al.  Accumulation of 
advanced oxidation protein products induces 
podocyte apoptosis and deletion through 
NADPH-dependent mechanisms .  Kidney Int  2009 ; 
 76 :  1148 – 1160 . 
 10 .  Shankland  SJ .  The podocyte’s response to injury: 
role in proteinuria and glomerulosclerosis .  Kidney 
Int  2006 ;  69 :  2131 – 2147 . 
 11 .  Li  Y ,  Kang  YS ,  Dai  C  et al.  Epithelial-to-
mesenchymal transition is a potential 
pathway leading to podocyte dysfunction 
and proteinuria .  Am J Pathol  2008 ;  172 :  
299 – 308 . 
 12 .  Okamura  DM ,  Pennathur  S ,  Pasichnyk  K  et al.  CD36 
regulates oxidative stress and inflammation in 
hypercholesterolemic CKD .  J Am Soc Nephrol  2009 ; 
 20 :  495 – 505 . 
see original article on page 1199
 It is well known that cardiovascular dis-
ease is a signifi cant cause of death in renal 
transplant patients and may account for 
47 % of all deaths in this population. 1 Th e 
increased propensity for cardiovascular 
disease is thought to stem from the inter-
play of immunosuppressive medications, 
most notably calcineurin inhibitors and 
corticosteroids. Th e sequelae of taking 
these medications in the post-transplan-
tation period include the development of 
weight gain, hyperlipidemia, hyperten-
sion, and glucose intolerance, which in 
combination describe metabolic syn-
drome (MS). 2,3 In addition to accelerating 
post-transplantation cardiovascular dis-
ease, MS has been thought to be a risk 
factor for chronic renal allograft  dysfunc-
tion. 4 MS has been reported to be as high 
as 57 % in the fi rst year following trans-
plantation. 5 MS is a dynamic disorder, 
and its development probably arises 
from the interaction of genetic makeup 
and lifestyle. Nafar and colleagues 6 
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 The incidence of metabolic syndrome (MS) in renal transplant patients is 
unacceptably high. Dietary intake may ameliorate or worsen the 
potential for the development of MS.  The choice of immunosuppression 
also plays a role. Continued effort to find beneficial dietary 
combinations is essential while ongoing research evolves to find 
newer immunosuppressive medications with less adverse metabolic 
side effects. 
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(this issue) examine the eff ects of diet 
on the development of MS. 
 Th e study observed the propensity for 
developing MS in an Iranian population 
on the basis of dietary intake. Three 
dietary patterns were delineated follow-
ing completion of a food frequency 
questionnaire 2 months aft er transplan-
tation: Fats and Sugars, Whole Grain, 
and Mediterranean. Th e Fats and Sugars 
pattern is characterized by consumption 
of higher portions of refi ned sugar, satu-
rated fat, and processed foods, which con-
trasts with the predominant consumption 
of low-fat products, vegetables, legumes, 
and fruits in the Mediterranean dietary 
pattern. Th e Whole Grain pattern is char-
acterized by higher consumption of whole 
grains such as barley bread and dark Ira-
nian breads. In all, 160 patients were 
enrolled and were observed for one year 
aft er transplantation during the period 
from 2004 to 2007. Exclusion criteria 
included a history of pretransplantation 
diabetes, prevalent MS, and a history of 
cancer. All patients were on  ‘ standard tri-
ple immunosuppression ’ consisting of 
cyclosporine, prednisolone, and myco-
phenolate mofetil or azathioprine and had 
stable renal function. Note that none of 
the patients were on tacrolimus. 
 Body mass index, blood pressure, lipids, 
blood glucose, and serum creatinine were 
similar among the three dietary groups at 
baseline, with the following exceptions: 
triglycerides were elevated in the Fats and 
Sugars group, and fasting blood sugar was 
elevated in the Whole Grain group. 
Demographic characteristics such as age, 
sex, level of physical activity, and cumula-
tive steroid usage were balanced between 
the three dietary groups. Th roughout the 
fi rst year aft er the transplant, the patients 
were monitored for the development of 
MS, defi ned by the presence of three or 
more of the following: obesity, low high-
density lipoprotein (HDL), high serum 
triglycerides, elevated blood pressure, and 
abnormal glucose homeostasis. Th e inves-
tigators concluded that those patients 
adhering to a diet rich in Fats and Sugars 
had a higher likelihood of developing MS, 
high blood pressure, high triglycerides, 
and low HDL, whereas those patients 
adhering to the Mediterranean diet 
were far less likely to develop MS, high 
blood pressure, or abnormal fasting 
blood sugar. Patients in the Whole Grain 
group were not shown to be at increased 
risk of developing MS or any other 
parameter studied. 
 Although numerous studies have 
underscored the validity of the Mediter-
ranean diet in reducing the incidence of 
MS and cardiovascular disease, this one 
was unique in studying a transplant popu-
lation whose members inherently have 
other confounding variables. 6,7 How the 
investigators came to these conclusions 
will be examined and discussed. 
 It is interesting that diff erences in MS 
between the Mediterranean diet and the 
Fats and Sugars diet were not evident until 
adjustments were made for total energy 
intake. Th e group on the Fats and Sugars 
diet had a higher energy intake than the 
group on the Mediterranean diet. Because 
of this difference, one could surmise 
before any adjustments were made that 
the group on the Fats and Sugars diet 
would be more likely to develop MS. Th e 
authors also evaluated their data using 
other statistical models, adjusting for age, 
sex, smoking, physical activity, dialysis 
mode and duration before transplanta-
tion, menopausal status, family history of 
diabetes and stroke, and cumulative ster-
oid dose at one year aft er transplantation, 
but they did not fi nd diff erences in the 
development of MS between the dietary 
patterns. Why diff erences were not found 
is unclear. Could transplant medications 
such as corticosteroids and calcineurin 
inhibitors have negated any benefi t from 
the Mediterranean diet? ( Figure 1 ). Could 
it also be related to sustained dietary 
transgressions stemming from the eupho-
ria of having a transplant and no longer 
being confi ned to a strict dialysis diet? It 
is unclear whether any subsequent food 
frequency questionnaire tests were taken 
to ensure adherence to the dietary pattern 
that was established with the initial 
screening. Assuming that no follow-up 
food frequency questionnaire was admin-
istered, it is not known whether continued 
compliance within a dietary pattern was 
maintained. If patient adherence to a cer-
tain dietary pattern changed during the 
allotted time of the study, the lack of sta-
tistical signifi cance achieved would be 
understandable. 
 Looking closely at the authors ’ conclu-
sions that the group on the Fats and 
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 Figure 1  |  The mechanism of transplant medicine in the development of metabolic 
syndrome.  HMG, 3-hydroxy-3-methylglutaryl; LDL, low-density lipoprotein; VLDL, very-low-
density lipoprotein. 
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 Sugars diet was more likely to have ele-
vated triglycerides, high blood pressure, 
and low HDL, and that the group on the 
Mediterranean diet was less likely to 
develop high blood pressure and abnor-
mal glucose homeostasis, some areas of 
concern arise. Th e confi dence interval for 
lower odds for high blood pressure and 
high fasting blood sugar in the Mediter-
ranean group crossed 1 in both instances, 
while the confi dence interval for the three 
categories in the Fats and Sugars group 
never crossed 1.  Th erefore, the only con-
clusion that can be made is that the Fats 
and Sugars group had higher odds of 
developing high blood pressure, high 
triglycerides, and low HDL levels. 
 Assuming that the Mediterranean diet 
does indeed reduce the development of 
MS in the post-transplantation patient, 
one must consider the applicability of this 
diet in the Western world. Given the 
widespread availability of processed foods 
in the West, the majority of the people are 
consuming food items that would fall in 
the Fats and Sugars group. Because of the 
cultural dietary diff erences between Iran 
and the Western world, compliance with 
a Mediterranean diet may be problematic. 
Such a change in dietary pattern would 
require a drastic cultural change that is 
not likely to occur quickly. 
 Th is study, on the contrary, may stimu-
late investigators in the West to perform 
dietary analysis of regional food-con-
sumption norms on transplant patients. It 
would be worthwhile to see how dietary 
patterns differ and how these patterns 
aff ect the development of MS. Additional 
long-term studies should assess the impact 
of these diets on cardiovascular mortality 
and graft  survival. Given the prevalent use 
of tacrolimus and its propensity to cause 
diabetes, future studies should also 
 incorporate patients on this medication, 
as this may be an independent variable in 
the development of MS. 
 At the present time, the incidence of 
MS in the post-transplantation patient is 
unacceptably high, and the proposed 
treatment of corticosteroid withdrawal 
and statin drug implementation has 
resulted in a higher risk of acute rejec-
tion. 8 Continued eff ort to fi nd benefi cial 
dietary combinations is essential while 
ongoing research evolves to fi nd newer 
immunosuppressive medications with 
less adverse metabolic side eff ects. Th is 
study has highlighted something we 
already knew — that diets high in fats and 
sugars are detrimental to our health — but 
does not necessarily show that the Medi-
terranean diet was benefi cial in the trans-
plant patient. Hopefully this study will 
stimulate further analysis of different 
dietary combinations according to cul-
tural norms so that a more applicable and 
less onerous lifestyle modifi cation can be 
implemented. 
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